Phase I Trial of Recombinant Human γ-Interferon and Recombinant Human Tumor Necrosis Factor in Patients with Advanced Gastrointestinal Cancer

James L. Abbruzzese; Bernard Levin; Jaffer A. Ajani; Jack S. Faintuch; Samuel Saks; Yehuda Z. Patt; Charlene Edwards; Karen Ende; Jordan U. Gutterman

Phase I Trial of Recombinant Human γ-Interferon and Recombinant Human Tumor Necrosis Factor in Patients with Advanced Gastrointestinal Cancer

James L. Abbruzzese, Bernard Levin, Jaffer A. Ajani, Jack S. Faintuch, Samuel Saks, Yehuda Z. Patt, Charlene Edwards, Karen Ende, Jordan U. Gutterman

GI Medical Oncology

Research output: Contribution to journal › Article › peer-review

72 Scopus citations

Abstract

Recombinant human γ-interferon and recombinant human tumor necrosis factor are two representatives of a new class of antineoplastic agents. In vitro studies have suggested synergistic cytotoxic activities when the agents are combined. We report a phase I study of these two agents when administered daily for 5 consecutive days every 2 weeks in patients with advanced gastrointestinal cancers. Toxicity resulting from these agents was significant with hyperbilirubinemia representing the dose-limiting toxicity. Significant, although transient, myelosuppression was also observed. The maximal tolerated doses were 150 Mg/m2/day for 5 days for each agent. Suggestive antineoplastic activity in biliary and pancreatic cancer was observed. Phase II trials of this combination are currently in progress.

Original language	English (US)
Pages (from-to)	4057-4061
Number of pages	5
Journal	Cancer Research
Volume	49
Issue number	14
State	Published - Jul 15 1989

ASJC Scopus subject areas

Oncology
Cancer Research

Cite this

@article{de85d64390d240d3b33f28fc3e0ec486,

title = "Phase I Trial of Recombinant Human γ-Interferon and Recombinant Human Tumor Necrosis Factor in Patients with Advanced Gastrointestinal Cancer",

abstract = "Recombinant human γ-interferon and recombinant human tumor necrosis factor are two representatives of a new class of antineoplastic agents. In vitro studies have suggested synergistic cytotoxic activities when the agents are combined. We report a phase I study of these two agents when administered daily for 5 consecutive days every 2 weeks in patients with advanced gastrointestinal cancers. Toxicity resulting from these agents was significant with hyperbilirubinemia representing the dose-limiting toxicity. Significant, although transient, myelosuppression was also observed. The maximal tolerated doses were 150 Mg/m2/day for 5 days for each agent. Suggestive antineoplastic activity in biliary and pancreatic cancer was observed. Phase II trials of this combination are currently in progress.",

author = "Abbruzzese, {James L.} and Bernard Levin and Ajani, {Jaffer A.} and Faintuch, {Jack S.} and Samuel Saks and Patt, {Yehuda Z.} and Charlene Edwards and Karen Ende and Gutterman, {Jordan U.}",

year = "1989",

month = jul,

day = "15",

language = "English (US)",

volume = "49",

pages = "4057--4061",

journal = "Cancer Research",

issn = "0008-5472",

number = "14",

}

TY - JOUR

T1 - Phase I Trial of Recombinant Human γ-Interferon and Recombinant Human Tumor Necrosis Factor in Patients with Advanced Gastrointestinal Cancer

AU - Abbruzzese, James L.

AU - Levin, Bernard

AU - Ajani, Jaffer A.

AU - Faintuch, Jack S.

AU - Saks, Samuel

AU - Patt, Yehuda Z.

AU - Edwards, Charlene

AU - Ende, Karen

AU - Gutterman, Jordan U.

PY - 1989/7/15

Y1 - 1989/7/15

N2 - Recombinant human γ-interferon and recombinant human tumor necrosis factor are two representatives of a new class of antineoplastic agents. In vitro studies have suggested synergistic cytotoxic activities when the agents are combined. We report a phase I study of these two agents when administered daily for 5 consecutive days every 2 weeks in patients with advanced gastrointestinal cancers. Toxicity resulting from these agents was significant with hyperbilirubinemia representing the dose-limiting toxicity. Significant, although transient, myelosuppression was also observed. The maximal tolerated doses were 150 Mg/m2/day for 5 days for each agent. Suggestive antineoplastic activity in biliary and pancreatic cancer was observed. Phase II trials of this combination are currently in progress.

AB - Recombinant human γ-interferon and recombinant human tumor necrosis factor are two representatives of a new class of antineoplastic agents. In vitro studies have suggested synergistic cytotoxic activities when the agents are combined. We report a phase I study of these two agents when administered daily for 5 consecutive days every 2 weeks in patients with advanced gastrointestinal cancers. Toxicity resulting from these agents was significant with hyperbilirubinemia representing the dose-limiting toxicity. Significant, although transient, myelosuppression was also observed. The maximal tolerated doses were 150 Mg/m2/day for 5 days for each agent. Suggestive antineoplastic activity in biliary and pancreatic cancer was observed. Phase II trials of this combination are currently in progress.

UR - http://www.scopus.com/inward/record.url?scp=0024333876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024333876&partnerID=8YFLogxK

M3 - Article

C2 - 2500234

AN - SCOPUS:0024333876

SN - 0008-5472

VL - 49

SP - 4057

EP - 4061

JO - Cancer Research

JF - Cancer Research

IS - 14

ER -

Phase I Trial of Recombinant Human γ-Interferon and Recombinant Human Tumor Necrosis Factor in Patients with Advanced Gastrointestinal Cancer

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this